BUZZ-BioRestorative rises on preliminary data for bone disease cell therapy

Reuters11-13 21:00

** Shares of drug developer BioRestorative Therapies

rise ~7% to $1.75 premarket

** Co reports preliminary data from ongoing mid-stage study testing BRTX-100, its lead cell therapy candidate to treat chronic lumbar disc disease

** Lumbar disc disease, also known as degenerative disc disease, occurs when spinal discs in lower back area begins to wear away

** No serious side-effects were reported in 10 safety run-in subjects, BRTX says

** Co says blinded data from 10 trial participants showed BRTX-100 helped improve pain and function

** Up to last close, stock down ~6% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment